Precipio (NASDAQ:PRPO – Get Free Report) and Privia Health Group (NASDAQ:PRVA – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.
Risk and Volatility
Precipio has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Privia Health Group has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations and price targets for Precipio and Privia Health Group, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Precipio | 1 | 0 | 0 | 0 | 1.00 |
| Privia Health Group | 0 | 3 | 13 | 0 | 2.81 |
Profitability
This table compares Precipio and Privia Health Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Precipio | -5.50% | -10.07% | -6.71% |
| Privia Health Group | 0.89% | 2.52% | 1.47% |
Earnings and Valuation
This table compares Precipio and Privia Health Group”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Precipio | $18.53 million | 2.31 | -$4.29 million | ($0.82) | -29.82 |
| Privia Health Group | $1.74 billion | 1.69 | $14.39 million | $0.13 | 183.00 |
Privia Health Group has higher revenue and earnings than Precipio. Precipio is trading at a lower price-to-earnings ratio than Privia Health Group, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
10.5% of Precipio shares are held by institutional investors. Comparatively, 94.5% of Privia Health Group shares are held by institutional investors. 16.9% of Precipio shares are held by insiders. Comparatively, 10.7% of Privia Health Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Privia Health Group beats Precipio on 11 of the 14 factors compared between the two stocks.
About Precipio
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
About Privia Health Group
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia.
Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.
